Death receptor 6 (DR6) is required for mouse B16 tumor angiogenesis via the NF-κB, P38 MAPK and STAT3 pathways

Oncogenesis

Volumn 5, Issue , 2016, Pages

  Yang, X ^a   Shi, B ^a   Li, L ^a   Xu, Z ^a   Ge, Y ^a   Shi, J ^a   Liu, Y ^a   Zheng, D ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; DEATH RECEPTOR 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN D;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOKINE RELEASE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; VASCULAR TUMOR;

EID: 84960907863     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2016.16     Document Type: Article

References (26)

1. Pan G, Bauer JH, Haridas V, Wang S, Liu D, Yu G., et al. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett 1998; 431: 351-356
2. Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D., et al. Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther 2011; 12: 169-180
3. Kasof GM, Lu JJ, Liu D, Speer B, Mongan KN, Gomes BC., et al. Tumor necrosis factor-Alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. Oncogene 2001; 20: 7965-7975
4. Klima M, Brouckova A, Koc M, Andera L. T-cell activation triggers death receptor-6 expression in a NF-kappaB and NF-AT dependent manner. Mol Immunol 2011; 48: 1439-1447
5. Liu J, Na S, Glasebrook A, Fox N, Solenberg PJ, Zhang Q., et al. Enhanced CD4+ T cell proliferation and Th2 cytokine production in DR6-deficient mice. Immunity 2001; 15: 23-34
6. Tam SJ, Richmond DL, Kaminker JS, Modrusan Z, Martin-McNulty B, Cao TC., et al. Death receptors DR6 and TROY regulate brain vascular development. Dev Cell 2012; 22: 403-417
7. Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med 2013; 273: 114-127
8. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003; 22: 1517-1527
9. Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L., et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 2013; 15: 848-862
10. Wu CT, Chen MF, Chen WC, Hsieh CC. The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol 2013; 8: 159
11. Mi S, Lee X, Hu Y, Ji B, Shao Z, Yang W., et al. Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination. Nat Med 2011; 17: 816-821
12. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009; 457: 981-989
13. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007; 102: 129-135
14. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308
15. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C., et al. CD95 promotes tumour growth. Nature 2010; 465: 492-496
16. Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 2009; 182: 3801-3808
17. Lavrik IN, Golks A, Riess D, Bentele M, Eils R, Krammer PH. Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J Biol Chem 2007; 282: 13664-13671
18. Zeng L, Li T, Xu DC, Liu J, Mao G, Cui MZ., et al. Death receptor 6 induces apoptosis not through type I or type II pathways, but via a unique mitochondriadependent pathway by interacting with Bax protein. J Biol Chem 2012; 287: 29125-29133
19. Urban P, Rabajdova MB, Varga J, Kruzliak P, Fialkovicova V, Durovcova E., et al. Vascular marker expression during the development of various types of gynaecological malignancy. Tumour Biol 2014; 35: 11229-11235
20. Bilecova-Rabajdova M, Urban P, Gregova K, Varga J, Fialkovicova V, Kruzliak P., et al. Breast carcinoma progression and tumour vascular markers related to apoptotic mechanisms. Dis Markers 2014; 2014: 156034
21. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008; 118: 3367-3377
22. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51
23. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 2000; 190: 430-436
24. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 2000; 192: 150-158
25. Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly-A mini-review. Gerontology 2010; 56: 303-309
26. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2: 619-626